Desmoid tumors were in the spotlight at the 2022 Connective Tissue Oncology Society (CTOS) annual conference in Vancouver, Canada last weekend!
Designated the “Sarcoma of the Year” for this year’s event, “Desmoid Fibromatosis” was the focus of an informative special session on Saturday which featured presentations on active surveillance, cryoablation, metronomic therapy, and the DeFi Phase 3 clinical trial results.
The session was chaired by Torsten Nielsen, MD, PhD, (Department of Pathology at Vancouver General Hospital) with moderators Chiara Colombo, N/A, MD (Fondazione IRCCS Istituto Nazionale dei Tumori) and DTRF Medical Advisory board member Bernd Kasper, MD PhD (University of Heidelberg, Mannheim University Medical Center).
We are grateful to CTOS for giving desmoid tumors this highlight, and to the doctors and researchers involved in the hopeful research presented to the global sarcoma medical community.
For more information, watch the recordings of the 2022 DTRF Patient Meeting Webinars on two of the topics mentioned at CTOS:
DTRF Patient Meeting Webinar #2: Cryoablation
DTRF Patient Meeting Webinar #2: Nirogacestat – DeFi Phase 3 Results
